| Name | Recombinant Human Neprilysin (N-8His) |
| Purity | Greater than 95% as determined by reducing SDS-PAGE |
| Endotoxin level | <1 EU/µg as determined by LAL test. |
| Construction | Recombinant Human Neprilysin is produced by our Mammalian expression system and the target gene encoding Tyr52-Trp750 is expressed with a 8His tag at the N-terminus. |
| Accession # | P08473 |
| Host | Human Cells |
| Species | Human |
| Predicted Molecular Mass | 80.9 KDa |
| Buffer | Supplied as a 0.2 μm filtered solution of PBS, pH 7.4. |
| Form | Liquid |
| Shipping | The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below. |
| Stability&Storage | Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles. |
Alternative Names
Neprilysin; Atriopeptidase; Common acute lymphocytic leukemia antigen; CALLA; Enkephalinase; Neutral endopeptidase 24.11; NEP; Neutral endopeptidase; Skin fibroblast elastase; SFE; CD10; MME; EPN
Background
Neprilysin/CD10(NEP) is a zinc metallopeptidase expressed at the cell surface of a variety of cells. The functions is both as an endopeptidase with a thermolysin-like specificity and as a dipeptidyl-carboxypeptidase. NEP has been shown to be involved in the degradation of enkephalins in the mammalian brain and the inactivation of circulating atrial natriuretic peptide. NEP has also been identified as the common acute lymphocytic leukemia antigen (CALLA), and is expressed on the surface of lymphocytes in some disease states. These and other observations have resulted in considerable interest in NEP as a target for analgesics and antihypertensive drugs. NEP is also a major degrading enzyme of amyloid β peptide (Aβ) in the brain, indicating that down-regulation of NEP activity, which could be caused by aging, can contribute to the development of Alzheimer’s disease by promoting Aβ accumulation.
Note
For Research Use Only , Not for Diagnostic Use.